Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From D-Pharm Ltd.
Novartis is trying its luck with capmatinib on the accelerated assessment front at the European Medicines Agency. Gilead and Astellas/Seagen have secured fast-track review for their respective potential new products while Sesen Bio and Amryt Pharma are dealing with rejection.
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
The Dublin-based drugmaker, powered by climbing revenues of Lojuxta and Myalept, is preparing its launch teams for Filsuvez, which has the potential to become the first treatment approved for epidermolysis bullosa and the company is banking on speedy regulatory reviews.
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Thrombotech Ltd.